Micardis

Micardis is a brand name of telmisartan, approved by the FDA in the following formulation(s):

MICARDIS (telmisartan - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: November 10, 1998
  
  Strength(s): 40MG, 80MG ^[RLD]


• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: April 4, 2000
  
  Strength(s): 20MG
  

Has a generic version of Micardis been approved?

No. There is currently no therapeutically equivalent version of Micardis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Micardis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Benzimidazoles useful as angiotensin-11 antagonists
  Patent 5,591,762
  Issued: January 7, 1997
  Inventor(s): Hauel; Norbert & Narr, deceased; Berthold & Ries; Uwe & van Meel; Jacobus C. A. & Wienen; Wolfgang & Entzeroth; Michael
  Assignee(s): Dr. Karl Thomae GmbH
  Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
  
  Patent expiration dates:
  
  
  • January 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
  
  
  
  • January 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Polymorphs of telmisartan
  Patent 6,358,986
  Issued: March 19, 2002
  Inventor(s): Heinrich; Schneider
  Assignee(s): Boehringer Ingelheim Pharma KG
  The invention relates to polymorphs of 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • January 10, 2020
    
  
  



• 
  Use of inhibitors of the renin-angiotensin system
  Patent 7,998,953
  Issued: August 16, 2011
  Inventor(s): Montgomery; Hugh Edward & Martin; John Francis & Erusalimsky; Jorge Daniel
  Assignee(s): Ark Therapeutics Group, p.l.c.
  It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
  
  Patent expiration dates:
  
  
  • June 6, 2020
    
    ✓ 
    Patent use: REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
  
  



• 
  Use of inhibitors of the renin-angiotensin system
  Patent 8,003,679
  Issued: August 23, 2011
  Inventor(s): Montgomery; Hugh Edward & Martin; John Francis & Erusalimsky; Jorge Daniel
  Assignee(s): ArkTherapeutics Group, plc
  Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.
  
  Patent expiration dates:
  
  
  • October 6, 2022
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF STROKE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 16, 2012 - MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
  
  

See also...

• Micardis Consumer Information (Drugs.com)
• Micardis Consumer Information (Wolters Kluwer)
• Micardis Consumer Information (Cerner Multum)
• Micardis Advanced Consumer Information (Micromedex)
• Micardis AHFS DI Monographs (ASHP)
• Telmisartan Consumer Information (Wolters Kluwer)
• Telmisartan Consumer Information (Cerner Multum)
• Telmisartan Advanced Consumer Information (Micromedex)
• Telmisartan AHFS DI Monographs (ASHP)